Related Experiment Video
Updated: Aug 14, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Clopidogrel use in coronary artery disease
Aaron L Baggish1, Marc S Sabatine
1Department of Cardiology, Massachusetts General Hospital, Boston, MA, USA. abaggish@partners.org
Insights
Clopidogrel, an adenosine diphosphate receptor antagonist, effectively inhibits platelet activation. Its benefits are well-established for patients with stable coronary artery disease and acute coronary syndromes.
Area of Science:
- Cardiology
- Pharmacology
- Hematology
Background:
- Platelet activation is key in acute coronary syndromes.
- Clopidogrel is an oral thienopyridine and adenosine diphosphate receptor antagonist.
- It inhibits platelet activation, crucial for cardiovascular events.
Purpose of the Study:
- To review clopidogrel's pharmacology.
- To highlight clopidogrel trial results in acute coronary syndromes.
- To identify areas of uncertainty and future research directions.
Main Methods:
- Review of clopidogrel pharmacology.
- Analysis of clinical trial data in acute coronary syndromes.
- Synthesis of existing literature on clopidogrel efficacy.
Main Results:
- Clopidogrel benefits are established in stable coronary artery disease and acute coronary syndromes.
- The drug's utility has been evaluated in numerous patient trials.
- Evidence supports its role in preventing thrombotic events.
Conclusions:
- Clopidogrel is a vital therapeutic agent for acute coronary syndromes.
- Further research is needed to address remaining uncertainties.
- Optimal use in various clinical settings continues to be explored.
Abstract:
Platelet adhesion, activation and aggregation are central to the pathophysiology of the acute coronary syndromes. Clopidogrel, an oral thienopyridine derivative, is a platelet adenosine diphosphate receptor antagonist capable of inhibiting platelet activation. During the last decade, the utility of clopidogrel has been evaluated in several common clinical scenarios in a large number of patients. The benefits of clopidogrel in patients with stable coronary artery disease undergoing elective percutaneous coronary interventions and in patients presenting with acute coronary syndromes are now well established. This review outlines the pharmacology of clopidogrel, highlights the results of clopidogrel trials in the setting of acute coronary syndromes, and presents areas of uncertainty and potential future work.
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease IV: Preventive Measures
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease I: Introduction
